Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jan;47(1-3):139-44.
doi: 10.1007/s10616-005-3758-3.

In vivo Neuroprotective Activity of Epopeptide AB Against Ischemic Damage

Masaya Nagao  1 , Tong-Chun Wen, Masaya Okamoto, Kazuhiro Irie, Takeshi Takaku, Masahiro Sakanaka
Affiliations

In vivo Neuroprotective Activity of Epopeptide AB Against Ischemic Damage

Masaya Nagao et al. Cytotechnology. 2005 Jan.

Abstract

Erythropoietin (Epo) is a hematopoietic factor, which stimulates proliferation and differentiation of erythroid precursor cells. Epo also functions as a neuroprotective factor and protects neurons from ischemic damage. Recently a 17-mer peptide sequence (Epopeptide AB) in Epo (AEHCSLNENITVPDTKV) with a neuroprotective function was reported. In this study, we showed in vivo evidence that Epopeptide AB protected neurons from ischemic damage at similar dose compared to Epo. Epopeptide AB could not stimulate the proliferation of Epo-dependent growing murine myeloid Ep-FDC-P2 cells and also did not compete the proliferative function of Epo on these cells. Together with these results, Epopeptide AB did not transduce signals through direct binding to the known Epo receptor on hematopoietic cells but has neuroprotective activity against ischemia.

PubMed Disclaimer

References

    1. Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q.W., Smart J., Su-Rick C.J., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U.S.A. 2004;101:14,907–14,912. doi: 10.1073/pnas.0406491101. - DOI - PMC - PubMed
    1. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., Cerami A. Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U.S.A. 2000;97:10,526–10,531. doi: 10.1073/pnas.97.19.10526. - DOI - PMC - PubMed
    1. Campana W.M., Misasi R., O’Brien J.S. Identification of a neurotrophic sequence in erythropoietin. Int. J. Mol. Med. 1998;1:235–241. - PubMed
    1. Irie K., Oie K., Nakahara A., Yanai Y., Ohigashi H., Wender P.A., Fukuda H., Konishi H., Kikkawa U. Molecular basis for protein kinase C isozyme-selective binding: the synthesis, folding, and phorbol ester binding of the cysteine-rich domains of all protein kinase C isozymes. J. Am. Chem. Soc. 1998;120:9159–9167. doi: 10.1021/ja981087f. - DOI
    1. Junk A.K., Mammis A., Savitz S.I., Singh M., Roth S., Malhotra S., Rosenbaum P.S., Cerami A., Brines M., Rosenbaum D.M. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 2002;99:10659–10664. doi: 10.1073/pnas.152321399. - DOI - PMC - PubMed